Advanced therapeutic strategies for chronic lung disease using nanoparticle-based drug delivery

Journal of Clinical Medicine

Volumn 5, Issue 9, 2016, Pages

  Yhee, Ji Young ^a   Im, Jintaek ^a   Nho, Richard Seonghun ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Biodistribution; Lung diseases; Nanoparticle; Pulmonary delivery; Therapy

Indexed keywords

DENDRIMER; MEPOLIZUMAB; NANOPARTICLE;

CHRONIC LUNG DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPUTER ASSISTED TOMOGRAPHY; CYSTIC FIBROSIS; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; FOOD AND DRUG ADMINISTRATION; HUMAN; INFLAMMATION; NONHUMAN; POLYPHARMACY; REVIEW;

EID: 85048823303     PISSN: None     EISSN: 20770383     Source Type: Journal    
DOI: 10.3390/jcm5090082     Document Type: Review

References (116)

1. World Health Organization. Global Tuberculosis Report 2013;World Health Organization: Geneva, Switzerland, 2013; pp. 6-27.
2. World Health Organization. Global Surveillance, Prevention and Control of Chronic Respiratory Diseases: A Comprehensive Approach; World Health Organization: Geneva, Switzerland, 2007; pp. 12-36.
3. Halbert, R.J.; Natoli, J.L.; Gano, A.; Badamgarav, E.; Buist, A.S.; Mannino, D.M. Global burden of COPD: Systematic review and meta-analysis. Eur. Respir. J. 2006, 28, 523-532. [CrossRef] [PubMed]
4. Masoli, M.; Fabian, D.; Holt, S.; Beasley, R.; Global Initiative for Asthma P. The global burden of asthma: Executive summary of the GINA Dissemination Committee report. Allergy 2004, 59, 469-478. [CrossRef] [PubMed]
5. Ley, B.; Collard, H.R. Epidemiology of idiopathic pulmonary fibrosis. Clin. Epidemiol. 2013, 5, 483-492. [CrossRef] [PubMed]
6. Raghu, G.; Weycker, D.; Edelsberg, J.; Bradford, W.Z.; Oster, G. Incidence and prevalence of idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2006, 174, 810-816. [CrossRef] [PubMed]
7. Ruppert, C.; Schmidt, R.; Grimminger, F.; Suzuki, Y.; Seeger, W.; Lehr, C.M.; Gunther, A. Chemical coupling of a monoclonal antisurfactant protein-B antibody to human urokinase for targeting surfactant-incorporating alveolar fibrin. Bioconjug. Chem. 2002, 13, 804-811. [CrossRef] [PubMed]
8. Durham, A.L.; Caramori, G.; Chung, K.F.; Adcock, I.M. Targeted anti-inflammatory therapeutics in asthma and chronic obstructive lung disease. Transl. Res. 2016, 167, 192-203. [CrossRef] [PubMed]
9. Baker, K.E.; Bonvini, S.J.; Donovan, C.; Foong, R.E.; Han, B.; Jha, A.; Shaifta, Y.; Smit, M.; Johnson, J.R.; Moir, L.M. Novel drug targets for asthma and COPD: Lessons learned from in vitro and in vivo models. Pulm. Pharmacol. Ther. 2014, 29, 181-198. [CrossRef] [PubMed]
10. Fujita, Y.; Takeshita, F.; Kuwano, K.; Ochiya, T. RNAi Therapeutic Platforms for Lung Diseases. Pharmaceuticals 2013, 6, 223-250. [CrossRef] [PubMed]
11. Meyer, K.C. Diagnosis and management of interstitial lung disease. Transl. Respir. Med. 2014, 2, 4. [CrossRef] [PubMed]
12. Burhan, E.; Ruesen, C.; Ruslami, R.; Ginanjar, A.; Mangunnegoro, H.; Ascobat, P.; Donders, R.; van Crevel, R.; Aarnoutse, R. Isoniazid, rifampin, and pyrazinamide plasma concentrations in relation to treatment response in Indonesian pulmonary tuberculosis patients. Antimicrob. Agents Chemother. 2013, 57, 3614-3619. [CrossRef] [PubMed]
13. Carvalho, T.C.; Peters, J.I.; Williams, R.O. Influence of particle size on regional lung deposition-What evidence is there? Int. J. Pharm. 2011, 406, 1-10. [CrossRef] [PubMed]
14. Bahadori, M.; Mohammadi, F. Nanomedicine for respiratory diseases. Tanaffos 2012, 11, 18-22. [PubMed]
15. Smola, M.; Vandamme, T.; Sokolowski, A. Nanocarriers as pulmonary drug delivery systems to treat and to diagnose respiratory and non respiratory diseases. Int. J. Nanomed. 2008, 3, 1-19.
16. Di Gioia, S.; Trapani, A.; Castellani, S.; Carbone, A.; Belgiovine, G.; Craparo, E.F.; Puglisi, G.; Cavallaro, G.; Trapani, G.; Conese, M. Nanocomplexes for gene therapy of respiratory diseases: Targeting and overcoming the mucus barrier. Pulm. Pharmacol. Ther. 2015, 34, 8-24. [CrossRef] [PubMed]
17. Ratemi, E.; Sultana Shaik, A.; Al Faraj, A.; Halwani, R. Alternative approaches for the treatment of airway diseases: Focus on nanoparticle medicine. Clin. Exp. Allergy 2016, 46, 1033-1042. [CrossRef] [PubMed]
18. Buzea, C.; Pacheco, I.I.; Robbie, K. Nanomaterials and nanoparticles: Sources and toxicity. Biointerphases 2007, 2, MR17-MR71. [CrossRef] [PubMed]
19. Oberdorster, G.; Oberdorster, E.; Oberdorster, J. Nanotoxicology: An emerging discipline evolving from studies of ultrafine particles. Environ. Health Perspect. 2005, 113, 823-839. [CrossRef] [PubMed]
20. Thurman, J.M.; Serkova, N.J. Non-invasive imaging to monitor lupus nephritis and neuropsychiatric systemic lupus erythematosus. F1000Research 2015, 4, 153. [PubMed]
21. Janib, S.M.; Moses, A.S.; MacKay, J.A. Imaging and drug delivery using theranostic nanoparticles. Adv. Drug Deliv. Rev. 2010, 62, 1052-1063. [CrossRef] [PubMed]
22. Yhee, J.Y.; Son, S.; Kim, S.H.; Park, K.; Choi, K.; Kwon, I.C. Self-assembled glycol chitosan nanoparticles for disease-specific theranostics. J. Control Release 2014, 193, 202-213. [CrossRef] [PubMed]
23. Chung, C.Y.; Yang, J.T.; Kuo, Y.C. Polybutylcyanoacrylate nanoparticles for delivering hormone response element-conjugated neurotrophin-3 to the brain of intracerebral hemorrhagic rats. Biomaterials 2013, 34, 9717-9727. [CrossRef] [PubMed]
24. Lee, S.J.; Lee, A.; Hwang, S.R.; Park, J.S.; Jang, J.; Huh, M.S.; Jo, D.G.; Yoon, S.Y.; Byun, Y.; Kim, S.H.; Kwon, I.C.; Youn, I.; Kim, K. TNF-alpha gene silencing using polymerized siRNA/thiolated glycol chitosan nanoparticles for rheumatoid arthritis. Mol. Ther. 2014, 22, 397-408. [CrossRef] [PubMed]
25. Sharma, H.S.; Ali, S.F.; Dong,W.; Tian, Z.R.; Patnaik, R.; Patnaik, S.; Sharma, A.; Boman, A.; Lek, P.; Seifert, E.; Lundstedt, T. Drug delivery to the spinal cord tagged with nanowire enhances neuroprotective efficacy and functional recovery following trauma to the rat spinal cord. Ann. N. Y. Acad. Sci. 2007, 1122, 197-218. [CrossRef] [PubMed]
26. Matsumura, Y.; Maeda, H. A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986, 46, 6387-6392. [PubMed]
27. Ngoune, R.; Peters, A.; von Elverfeldt, D.; Winkler, K.; Putz, G. Accumulating nanoparticles by EPR: A route of no return. J. Control Release 2016, 238, 58-70. [CrossRef] [PubMed]
28. Gupta, N.; Hatoum, H.; Dy, G.K. First line treatment of advanced non-small-cell lung cancer-Specific focus on albumin bound paclitaxel. Int. J. Nanomed. 2014, 9, 209-221.
29. Chang, H.I.; Yeh, M.K. Clinical development of liposome-based drugs: Formulation, characterization, and therapeutic efficacy. Int. J. Nanomed. 2012, 7, 49-60.
30. Ait-Oudhia, S.; Mager, D.E.; Straubinger, R.M. Application of pharmacokinetic and pharmacodynamic analysis to the development of liposomal formulations for oncology. Pharmaceutics 2014, 6, 137-174. [CrossRef] [PubMed]
31. Choi, H.S.; Ipe, B.I.; Misra, P.; Lee, J.H.; Bawendi, M.G.; Frangioni, J.V. Tissue- and organ-selective biodistribution of NIR fluorescent quantum dots. Nano Lett. 2009, 9, 2354-2359. [CrossRef] [PubMed]
32. Gipps, E.M.; Arshady, R.; Kreuter, J.; Groscurth, P.; Speiser, P.P. Distribution of polyhexyl cyanoacrylate nanoparticles in nude mice bearing human osteosarcoma. J. Pharm. Sci. 1986, 75, 256-258. [CrossRef] [PubMed]
33. Rolland, A.; Collet, B.; Le Verge, R.; Toujas, L. Blood clearance and organ distribution of intravenously administered polymethacrylic nanoparticles in mice. J. Pharm. Sci. 1989, 78, 481-484. [CrossRef] [PubMed]
34. Bazile, D.V.; Ropert, C.; Huve, P.; Verrecchia, T.; Marlard, M.; Frydman, A.; Veillard, M.; Spenlehauer, G. Body distribution of fully biodegradable [14C]-poly(lactic acid) nanoparticles coated with albumin after parenteral administration to rats. Biomaterials 1992, 13, 1093-1102. [CrossRef]
35. Azarmi, S.; Roa,W.H.; Lobenberg, R. Targeted delivery of nanoparticles for the treatment of lung diseases. Adv. Drug Deliv. Rev. 2008, 60, 863-875. [CrossRef] [PubMed]
36. Chen, J.H.; Wang, L.; Ling, R.; Li, Y.; Wang, Z.; Yao, Q.; Ma, Z. Body distribution of nanoparticle-containing adriamycin injected into the hepatic artery of hepatoma-bearing rats. Dig. Dis. Sci. 2004, 49, 1170-1173. [CrossRef] [PubMed]
37. Yeh, T.K.; Lu, Z.; Wientjes, M.G.; Au, J.L. Formulating paclitaxel in nanoparticles alters its disposition. Pharm. Res. 2005, 22, 867-874. [CrossRef] [PubMed]
38. Zara, G.P.; Cavalli, R.; Fundaro, A.; Bargoni, A.; Caputo, O.; Gasco, M.R. Pharmacokinetics of doxorubicin incorporated in solid lipid nanospheres (SLN). Pharmacol. Res. 1999, 40, 281-286. [CrossRef] [PubMed]
39. Santhi, K.; Dhanaraj, S.A.; Koshy,M.; Ponnusankar, S.; Suresh, B. Study of biodistribution ofmethotrexate-loaded bovine serum albumin nanospheres in mice. Drug Dev. Ind. Pharm. 2000, 26, 1293-1296. [CrossRef] [PubMed]
40. Lee, W.H.; Loo, C.Y.; Traini, D.; Young, P.M. Inhalation of nanoparticle-based drug for lung cancer treatment: Advantages and challenges. Asian J. Pharm. Sci. 2015, 10, 481-489. [CrossRef]
41. Savla, R.; Minko, T. Nanotechnology approaches for inhalation treatment of fibrosis. J. Drug Target. 2013, 21, 914-925. [CrossRef] [PubMed]
42. Kuzmov, A.; Minko, T. Nanotechnology approaches for inhalation treatment of lung diseases. J. Control Release 2015, 219, 500-518. [CrossRef] [PubMed]
43. Lehofer, B.; Bloder, F.; Jain, P.P.; Marsh, L.M.; Leitinger, G.; Olschewski, H.; Leber, R.; Olschewski, A.; Prassl, R. Impact of atomization technique on the stability and transport efficiency of nebulized liposomes harboring different surface characteristics. Eur. J. Pharm. Biopharm. 2014, 88, 1076-1085. [CrossRef]
44. Jiang, H.L.; Hong, S.H.; Kim, Y.K.; Islam, M.A.; Kim, H.J.; Choi, Y.J.; Nah, J.W.; Lee, K.H.; Han, K.W.; Chae, C.; et al. Aerosol delivery of spermine-based poly(amino ester)/Akt1 shRNA complexes for lung cancer gene therapy. Int. J. Pharm. 2011, 420, 256-265. [CrossRef] [PubMed]
45. Kawashima, Y.; Serigano, T.; Hino, T.; Yamamoto, H.; Takeuchi, H. A new powder design method to improve inhalation efficiency of pranlukast hydrate dry powder aerosols by surface modification with hydroxypropylmethylcellulose phthalate nanospheres. Pharm. Res. 1998, 15, 1748-1752. [CrossRef] [PubMed]
46. Sham, J.O.; Zhang, Y.; Finlay,W.H.; Roa,W.H.; Lobenberg, R. Formulation and characterization of spray-dried powders containing nanoparticles for aerosol delivery to the lung. Int. J. Pharm. 2004, 269, 457-467. [CrossRef] [PubMed]
47. Rudokas, M.; Najlah, M.; Alhnan, M.A.; Elhissi, A. Liposome Delivery Systems for Inhalation: A Critical Review Highlighting Formulation Issues and Anticancer Applications. Med. Princ. Pract. 2016, 25, 60-72. [CrossRef] [PubMed]
48. Winterhalter, M.; Frederik, P.M.; Vallner, J.J.; Lasic, D.D. Stealth(R) liposomes: From theory to product. Adv. Drug Deliv. Rev. 1997, 24, 165-177.
49. Allen, T.M. Liposomal drug formulations. Rationale for development and what we can expect for the future. Drugs 1998, 56, 747-756. [CrossRef] [PubMed]
50. Kumar, A.; Chen, F.; Mozhi, A.; Zhang, X.; Zhao, Y.; Xue, X.; Hao, Y.; Zhang, X.; Wang, P.C.; Liang, X.J. Innovative pharmaceutical development based on unique properties of nanoscale delivery formulation. Nanoscale 2013, 5, 8307-8325. [CrossRef] [PubMed]
51. Pilcer, G.; Amighi, K. Formulation strategy and use of excipients in pulmonary drug delivery. Int. J. Pharm. 2010, 392, 1-19. [CrossRef] [PubMed]
52. Van Rijt, S.H.; Bein, T.; Meiners, S. Medical nanoparticles for next generation drug delivery to the lungs. Eur. Respir. J. 2014, 44, 765-774. [CrossRef] [PubMed]
53. Muralidharan, P.; Malapit, M.; Mallory, E.; Hayes, D., Jr.; Mansour, H.M. Inhalable nanoparticulate powders for respiratory delivery. Nanomedicine 2015, 11, 1189-1199. [CrossRef] [PubMed]
54. Kaminskas, L.M.; McLeod, V.M.; Ryan, G.M.; Kelly, B.D.; Haynes, J.M.; Williamson, M.; Thienthong, N.; Owen, D.J.; Porter, C.J. Pulmonary administration of a doxorubicin-conjugated dendrimer enhances drug exposure to lung metastases and improves cancer therapy. J. Control Release 2014, 183, 18-26. [CrossRef] [PubMed]
55. Ryan, G.M.; Kaminskas, L.M.; Kelly, B.D.; Owen, D.J.; McIntosh, M.P.; Porter, C.J. Pulmonary administration of PEGylated polylysine dendrimers: Absorption from the lung versus retention within the lung is highly size-dependent. Mol. Pharm. 2013, 10, 2986-2995. [CrossRef] [PubMed]
56. Paranjpe, M.; Muller-Goymann, C.C. Nanoparticle-mediated pulmonary drug delivery: A review. Int. J. Mol. Sci. 2014, 15, 5852-5873. [CrossRef] [PubMed]
57. Chan, J.G.;Wong, J.; Zhou, Q.T.; Leung, S.S.; Chan, H.K. Advances in device and formulation technologies for pulmonary drug delivery. AAPS PharmSciTech 2014, 15, 882-897. [CrossRef] [PubMed]
58. Faiyazuddin, M.; Mujahid, M.; Hussain, T.; Siddiqui, H.H.; Bhatnagar, A.; Khar, R.K.; Ahmad, F.J. Aerodynamics and deposition effects of inhaled submicron drug aerosol in airway diseases. Recent Pat. Inflamm. Allergy Drug Discov. 2013, 7, 49-61. [CrossRef] [PubMed]
59. d’Angelo, I.; Perfetto, B.; Costabile, G.; Ambrosini, V.; Caputo, P.; Miro, A.; d’Emmanuele di Villa Bianca, R.; Sorrentino, R.; Donnarumma, G.; Quaglia, F.; Ungaro, F. Large Porous Particles for Sustained Release of a Decoy Oligonucelotide and Poly(ethylenimine): Potential for Combined Therapy of Chronic Pseudomonas aeruginosa Lung Infections. Biomacromolecules 2016, 17, 1561-1571. [CrossRef] [PubMed]
60. Elhissi, A.M.A.; Faizi, M.; Naji,W.F.; Gill, H.S.; Taylor, K.M.G. Physical stability and aerosol properties of liposomes delivered using an air-jet nebulizer and a novel micropump device with large mesh apertures. Int. J. Pharm. 2007, 334, 62-70. [CrossRef] [PubMed]
61. Niven, R.W. Delivery of biotherapeutics by inhalation aerosol. Crit. Rev. Ther. Drug Carr. Syst. 1995, 12, 151-231. [CrossRef] [PubMed]
62. Yhee, J.Y.; Son, S.; Kim, N.; Choi, K.; Kwon, I.C. Theranostic applications of organic nanoparticles for cancer treatment. Mrs Bull. 2014, 39, 239-249. [CrossRef]
63. Kim, T.; Hyeon, T. Applications of inorganic nanoparticles as therapeutic agents. Nanotechnology 2014, 25, 012001. [CrossRef] [PubMed]
64. Estella-Hermoso de Mendoza, A.; Campanero, M.A.; Mollinedo, F.; Blanco-Prieto, M.J. Lipid nanomedicines for anticancer drug therapy. J. Biomed. Nanotechnol. 2009, 5, 323-343. [CrossRef] [PubMed]
65. Nassimi, M.; Schleh, C.; Lauenstein, H.D.; Hussein, R.; Hoymann, H.G.; Koch,W.; Pohlmann, G.; Krug, N.; Sewald, K.; Rittinghausen, S.; Braun, A.; Muller-Goymann, C. A toxicological evaluation of inhaled solid lipid nanoparticles used as a potential drug delivery system for the lung. Eur. J. Pharm. Biopharm. 2010, 75, 107-116. [CrossRef] [PubMed]
66. Nassimi, M.; Schleh, C.; Lauenstein, H.D.; Hussein, R.; Lubbers, K.; Pohlmann, G.; Switalla, S.; Sewald, K.; Muller, M.; Krug, N.; Muller-Goymann, C.C.; Braun, A. Low cytotoxicity of solid lipid nanoparticles in in vitro and ex vivo lung models. Inhal. Toxicol. 2009, 21, 104-109. [CrossRef] [PubMed]
67. Patel, A.R.; Chougule, M.B.; Ian, T.; Patlolla, R.; Wang, G.; Singh, M. Efficacy of aerosolized celecoxib encapsulated nanostructured lipid carrier in non-small cell lung cancer in combination with docetaxel. Pharm. Res. 2013, 30, 1435-1446. [CrossRef] [PubMed]
68. Elhissi, A.M.A.; Islam, M.A.; Arafat, B.; Taylor, M.; Ahmed, W. Development and characterisation of freeze-dried liposomes containing two anti-asthma drugs. Micro Nano Lett. 2010, 5, 184-188. [CrossRef]
69. Hoesel, L.M.; Flierl, M.A.; Niederbichler, A.D.; Rittirsch, D.; McClintock, S.D.; Reuben, J.S.; Pianko, M.J.; Stone, W.; Yang, H.; Smith, M.; et al. Ability of antioxidant liposomes to prevent acute and progressive pulmonary injury. Antioxid. Redox Signal. 2008, 10, 973-981. [CrossRef] [PubMed]
70. Liu, C.; Shi, J.; Dai, Q.; Yin, X.; Zhang, X.; Zheng, A. In vitro and in vivo evaluation of ciprofloxacin liposomes for pulmonary administration. Drug Dev. Ind. Pharm. 2015, 41, 272-278. [CrossRef] [PubMed]
71. Jokerst, J.V.; Lobovkina, T.; Zare, R.N.; Gambhir, S.S. Nanoparticle PEGylation for imaging and therapy. Nanomedicine 2011, 6, 715-728. [CrossRef] [PubMed]
72. Van Vlerken, L.E.; Vyas, T.K.; Amiji, M.M. Poly(ethylene glycol)-modified nanocarriers for tumor-targeted and intracellular delivery. Pharm. Res. 2007, 24, 1405-1414. [CrossRef] [PubMed]
73. Schuster, B.S.; Suk, J.S.;Woodworth, G.F.; Hanes, J. Nanoparticle diffusion in respiratory mucus from humans without lung disease. Biomaterials 2013, 34, 3439-3446. [CrossRef] [PubMed]
74. Bivas-Benita, M.; Romeijn, S.; Junginger, H.E.; Borchard, G. PLGA-PEI nanoparticles for gene delivery to pulmonary epithelium. Eur. J. Pharm. Biopharm. 2004, 58, 1-6. [CrossRef] [PubMed]
75. Patnaik, S.; Gupta, K.C. Novel polyethylenimine-derived nanoparticles for in vivo gene delivery. Expert Opin. Drug Deliv. 2013, 10, 215-228. [CrossRef] [PubMed]
76. Ungaro, F.; d’Angelo, I.; Coletta, C.; d’Emmanuele di Villa Bianca, R.; Sorrentino, R.; Perfetto, B.; Tufano, M.A.; Miro, A.; La Rotonda, M.I.; Quaglia, F. Dry powders based on PLGA nanoparticles for pulmonary delivery of antibiotics: Modulation of encapsulation efficiency, release rate and lung deposition pattern by hydrophilic polymers. J. Control Release 2012, 157, 149-159. [CrossRef] [PubMed]
77. Seong, J.H.; Lee, K.M.; Kim, S.T.; Jin, S.E.; Kim, C.K. Polyethylenimine-based antisense oligodeoxynucleotides of IL-4 suppress the production of IL-4 in a murine model of airway inflammation. J. Gene Med. 2006, 8, 314-323. [CrossRef] [PubMed]
78. Surti, N.; Naik, S.; Bagchi, T.; Dwarkanath, B.S.; Misra, A. Intracellular delivery of nanoparticles of an antiasthmatic drug. AAPS PharmSciTech 2008, 9, 217-223. [CrossRef] [PubMed]
79. Pandey, R.; Sharma, A.; Zahoor, A.; Sharma, S.; Khuller, G.K.; Prasad, B. Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis. J. Antimicrob. Chemother. 2003, 52, 981-986. [CrossRef] [PubMed]
80. Kimura, S.; Egashira, K.; Chen, L.; Nakano, K.; Iwata, E.; Miyagawa, M.; Tsujimoto, H.; Hara, K.; Morishita, R.; Sueishi, K.; Tominaga, R.; Sunagawa, K. Nanoparticle-mediated delivery of nuclear factor kappaB decoy into lungs ameliorates monocrotaline-induced pulmonary arterial hypertension. Hypertension 2009, 53, 877-883. [CrossRef] [PubMed]
81. Kesharwani, P.; Jain, K.; Jain, N.K. Dendrimer as nanocarrier for drug delivery. Prog. Polym. Sci. 2014, 39, 268-307. [CrossRef]
82. Bharatwaj, B.; Mohammad, A.K.; Dimovski, R.; Cassio, F.L.; Bazito, R.C.; Conti, D.; Fu, Q.; Reineke, J.; da Rocha, S.R. Dendrimer nanocarriers for transport modulation across models of the pulmonary epithelium. Mol. Pharm. 2015, 12, 826-838. [CrossRef] [PubMed]
83. Bellini, R.G.; Guimaraes, A.P.; Pacheco, M.A.; Dias, D.M.; Furtado, V.R.; de Alencastro, R.B.; Horta, B.A. Association of the anti-tuberculosis drug rifampicin with a PAMAM dendrimer. J. Mol. Graph. Model. 2015, 60, 34-42. [CrossRef] [PubMed]
84. Inapagolla, R.; Guru, B.R.; Kurtoglu, Y.E.; Gao, X.; Lieh-Lai, M.; Bassett, D.J.; Kannan, R.M. In vivo efficacy of dendrimer-methylprednisolone conjugate formulation for the treatment of lung inflammation. Int. J. Pharm. 2010, 399, 140-147. [CrossRef] [PubMed]
85. Cho, E.C.; Glaus, C.; Chen, J.; Welch, M.J.; Xia, Y. Inorganic nanoparticle-based contrast agents for molecular imaging. Trends Mol. Med. 2010, 16, 561-573. [CrossRef] [PubMed]
86. Swierczewska, M.; Lee, S.; Chen, X. Inorganic nanoparticles for multimodal molecular imaging. Mol. Imaging 2011, 10, 3-16. [PubMed]
87. Ding, Y.; Jiang, Z.; Saha, K.; Kim, C.S.; Kim, S.T.; Landis, R.F.; Rotello, V.M. Gold nanoparticles for nucleic acid delivery. Mol. Ther. 2014, 22, 1075-1083. [CrossRef] [PubMed]
88. Capek, I.; Tiwari, A. DNA Engineered Noble Metal Nanoparticles: Fundamentals and State-of-the-Art of Nanobiotechnology; Wiley: New Jersey, NJ, USA, 2015; pp. 173-280.
89. Geiser, M.; Quaile, O.; Wenk, A.; Wigge, C.; Eigeldinger-Berthou, S.; Hirn, S.; Schaffler, M.; Schleh, C.; Moller, W.; Mall, M.A.; Kreyling, W.G. Cellular uptake and localization of inhaled gold nanoparticles in lungs of mice with chronic obstructive pulmonary disease. Part. Fibre Toxicol. 2013, 10, 19. [CrossRef] [PubMed]
90. Alkilany, A.M.; Murphy, C.J. Toxicity and cellular uptake of gold nanoparticles: What we have learned so far? J. Nanopart. Res. 2010, 12, 2313-2333. [CrossRef] [PubMed]
91. Chen, H.W.; Su, S.F.; Chien, C.T.; Lin, W.H.; Yu, S.L.; Chou, C.C.; Chen, J.J.; Yang, P.C. Titanium dioxide nanoparticles induce emphysema-like lung injury in mice. FASEB J. 2006, 20, 2393-2395. [CrossRef] [PubMed]
92. Shi, H.; Magaye, R.; Castranova, V.; Zhao, J. Titanium dioxide nanoparticles: A review of current toxicological data. Part Fibre Toxicol. 2013, 10, 15. [CrossRef] [PubMed]
93. Chandolu, V.; Dass, C.R. Treatment of lung cancer using nanoparticle drug delivery systems. Curr. Drug Discov. Technol. 2013, 10, 170-176. [CrossRef] [PubMed]
94. McLendon, J.M.; Joshi, S.R.; Sparks, J.; Matar, M.; Fewell, J.G.; Abe, K.; Oka, M.; McMurtry, I.F.; Gerthoffer,W.T. Lipid nanoparticle delivery of a microRNA-145 inhibitor improves experimental pulmonary hypertension. J. Control Release 2015, 210, 67-75. [CrossRef] [PubMed]
95. Wang,W.; Zhu, R.; Xie, Q.; Li, A.; Xiao, Y.; Li, K.; Liu, H.; Cui, D.; Chen, Y.;Wang, S. Enhanced bioavailability and efficiency of curcumin for the treatment of asthma by its formulation in solid lipid nanoparticles. Int. J. Nanomed. 2012, 7, 3667-3677. [CrossRef] [PubMed]
96. Montuschi, P.; Malerba, M.; Santini, G.; Miravitlles, M. Pharmacological treatment of chronic obstructive pulmonary disease: From evidence-based medicine to phenotyping. Drug Discov. Today 2014, 19, 1928-1935. [CrossRef] [PubMed]
97. Da Silva, A.L.; Santos, R.S.; Xisto, D.G.; Alonso Sdel, V.; Morales, M.M.; Rocco, P.R. Nanoparticle-based therapy for respiratory diseases. Anais da Academia Brasileira de Ciencias 2013, 85, 137-146. [CrossRef] [PubMed]
98. Joshi, M.; Misra, A.N. Pulmonary disposition of budesonide from liposomal dry powder inhaler. Methods Find Exp. Clin. Pharmacol. 2001, 23, 531-536. [CrossRef] [PubMed]
99. Konduri, K.S.; Nandedkar, S.; Duzgunes, N.; Suzara, V.; Artwohl, J.; Bunte, R.; Gangadharam, P.R. Efficacy of liposomal budesonide in experimental asthma. J. Allergy Clin. Immunol. 2003, 111, 321-327. [CrossRef] [PubMed]
100. Matsuo, Y.; Ishihara, T.; Ishizaki, J.; Miyamoto, K.; Higaki, M.; Yamashita, N. Effect of betamethasone phosphate loaded polymeric nanoparticles on a murine asthma model. Cell Immunol. 2009, 260, 33-38. [CrossRef] [PubMed]
101. Trivedi, R.; Redente, E.F.; Thakur, A.; Riches, D.W.; Kompella, U.B. Local delivery of biodegradable pirfenidone nanoparticles ameliorates bleomycin-induced pulmonary fibrosis in mice. Nanotechnology 2012, 23, 505101. [CrossRef] [PubMed]
102. Kolb, M.; Martin, G.; Medina, M.; Ask, K.; Gauldie, J. Gene therapy for pulmonary diseases. Chest 2006, 130, 879-884. [CrossRef] [PubMed]
103. Kong, X.; Hellermann, G.R.; Zhang,W.; Jena, P.; Kumar, M.; Behera, A.; Behera, S.; Lockey, R.; Mohapatra, S.S. Chitosan Interferon-gamma Nanogene Therapy for Lung Disease: Modulation of T-Cell and Dendritic Cell Immune Responses. Allergy Asthma Clin. Immunol. 2008, 4, 95-105. [CrossRef] [PubMed]
104. Hopkins, A.L. Network pharmacology: The next paradigm in drug discovery. Nat. Chem. Biol. 2008, 4, 682-690. [CrossRef] [PubMed]
105. Nair, P.; Pizzichini, M.M.; Kjarsgaard, M.; Inman, M.D.; Efthimiadis, A.; Pizzichini, E.; Hargreave, F.E.; O’Byrne, P.M. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N. Engl. J. Med. 2009, 360, 985-993. [CrossRef] [PubMed]
106. Pavord, I.D.; Korn, S.; Howarth, P.; Bleecker, E.R.; Buhl, R.; Keene, O.N.; Ortega, H.; Chanez, P. Mepolizumab for severe eosinophilic asthma (DREAM): A multicentre, double-blind, placebo-controlled trial. Lancet 2012, 380, 651-659. [CrossRef]
107. Boppana, N.B.; Devarajan, A.; Gopal, K.; Barathan, M.; Bakar, S.A.; Shankar, E.M.; Ebrahim, A.S.; Farooq, S.M. Blockade of CXCR2 signalling: A potential therapeutic target for preventing neutrophil-mediated inflammatory diseases. Exp. Biol. Med. 2014, 239, 509-518. [CrossRef] [PubMed]
108. Horiguchi, M.; Oiso, Y.; Sakai, H.; Motomura, T.; Yamashita, C. Pulmonary administration of phosphoinositide 3-kinase inhibitor is a curative treatment for chronic obstructive pulmonary disease by alveolar regeneration. J. Control Release 2015, 213, 112-119. [CrossRef] [PubMed]
109. Al Faraj, A.; Shaik, A.S.; Afzal, S.; Al Sayed, B.; Halwani, R. MR imaging and targeting of a specific alveolar macrophage subpopulation in LPS-induced COPD animal model using antibody-conjugated magnetic nanoparticles. Int. J. Nanomed. 2014, 9, 1491-1503. [CrossRef] [PubMed]
110. Bonner, J.C. Nanoparticles as a potential cause of pleural and interstitial lung disease. Proc. Am. Thorac. Soc. 2010, 7, 138-141. [CrossRef] [PubMed]
111. Ibrahim, B.M.; Park, S.; Han, B.; Yeo, Y. A strategy to deliver genes to cystic fibrosis lungs: A battle with environment. J. Control Release 2011, 155, 289-295. [CrossRef] [PubMed]
112. Suk, J.S.; Lai, S.K.; Wang, Y.Y.; Ensign, L.M.; Zeitlin, P.L.; Boyle, M.P.; Hanes, J. The penetration of fresh undiluted sputum expectorated by cystic fibrosis patients by non-adhesive polymer nanoparticles. Biomaterials 2009, 30, 2591-2597. [CrossRef] [PubMed]
113. Lai, S.K.; O’Hanlon, D.E.; Harrold, S.; Man, S.T.; Wang, Y.Y.; Cone, R.; Hanes, J. Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus. Proc. Natl. Acad. Sci. USA 2007, 104, 1482-1487. [CrossRef] [PubMed]
114. Broughton-Head, V.J.; Smith, J.R.; Shur, J.; Shute, J.K. Actin limits enhancement of nanoparticle diffusion through cystic fibrosis sputum by mucolytics. Pulm. Pharmacol. Ther. 2007, 20, 708-717. [CrossRef] [PubMed]
115. Yang, Y.; Tsifansky, M.D.; Shin, S.; Lin, Q.; Yeo, Y. Mannitol-Guided Delivery of Ciprofloxacin in Artificial Cystic Fibrosis Mucus Model. Biotechnol. Bioeng. 2010, 108, 1441-1449. [CrossRef] [PubMed]
116. Kim, N.; Duncan, G.A.; Hanes, J.; Suk, J.S. Barriers to inhaled gene therapy of obstructive lung diseases: A review. J. Control Release 2016, in press. [CrossRef] [PubMed]